{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:02:03Z","timestamp":1787702523616,"version":"build-2784847793"},"reference-count":101,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"AbbVie"},{"DOI":"10.13039\/100010875","name":"Amgen Canada","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010875","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100012317","name":"Astellas Pharma Canada","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012317","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008021","name":"BMS Canada","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008021","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Jazz Pharma Canada"},{"DOI":"10.13039\/100009009","name":"Novartis Canada","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009009","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100013739","name":"Pfizer Canada","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013739","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100023798","name":"Servier Canada","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100023798","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Taiho Canada"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>In the companion article in this issue of Current Oncology, \u2018Management of AML in Older Patients: An Updated Canadian Consensus\u2019, the authors have presented the third iteration of Canadian consensus guidelines on AML treatment in the elderly. While many aspects of AML treatment in the elderly have become better defined, some old questions remain and new questions and controversies have arisen. Here, we address three topics on which there is, at this time, no universal consensus. The first is the development and features of new risk-stratification systems specifically aimed at older, less-intensively treated patients. Several different systems now exist in parallel, potentially causing confusion amongst clinicians. The second topic is good-prognosis AML subtypes (IDH1- and NPM1-mutated AML). In the Canadian context, IDH1-mutated AML is of particular interest due to the new availability of ivosidenib in Canada. The third topic is adverse-risk AML subtypes (FLT3- and TP53-mutated AML). FLT3-mutated AML remains problematic, although it is anticipated that new drug approvals and measurable residual disease-based treatment approaches may alleviate this, at least in part. And in particular, TP53-mutated AML remains a major problem. Ongoing clinical trial enrollment is essential.<\/jats:p>","DOI":"10.3390\/curroncol33070431","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T06:09:09Z","timestamp":1784527749000},"page":"431","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Controversies in the Management of AML in Older Patients: A Canadian Perspective"],"prefix":"10.3390","volume":"33","author":[{"given":"Andre C.","family":"Schuh","sequence":"first","affiliation":[{"name":"Departments of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada"},{"name":"Department of Medicine, University of Toronto, Toronto ON M5S 1A8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9095-8789","authenticated-orcid":false,"given":"Joseph","family":"Brandwein","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, University of Alberta, Edmonton, AB T6G 2G3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Elsawy","sequence":"additional","affiliation":[{"name":"Division of Hematology and Hematologic Oncology, Department of Medicine, Dalhousie University, Halifax, NS B3H 2Y9, Canada"},{"name":"QEII Health Sciences Centre, Halifax, NS B3H 3A7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sanford","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of British Columbia, Vancouver, BC V5Z 1M9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5502-1480","authenticated-orcid":false,"given":"Brian","family":"Leber","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University, Hamilton, ON L8S 4L8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1182\/blood.V92.7.2322","article-title":"The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children\u2019s Leukaemia Working Parties","volume":"92","author":"Grimwade","year":"1998","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"Estey","year":"2010","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Estey","year":"2017","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood.2024024944","article-title":"Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine","volume":"144","author":"Pratz","year":"2024","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2023011757","article-title":"Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax","volume":"8","author":"Bataller","year":"2024","journal-title":"Blood Adv."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41408-025-01346-1","article-title":"Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms","volume":"15","author":"Gangat","year":"2025","journal-title":"Blood Cancer J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.1182\/bloodadvances.2024013685","article-title":"Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy","volume":"8","author":"Hoff","year":"2024","journal-title":"Blood Adv."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1158\/1078-0432.CCR-21-3467","article-title":"Impact of Venetoclax and Azacitidine in Treatment-Naive Patients with Acute Myeloid Leukemia and IDH1\/2 Mutations","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.1182\/bloodadvances.2025016399","article-title":"Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML","volume":"9","author":"Montesinos","year":"2025","journal-title":"Blood Adv."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/s41375-023-01999-6","article-title":"Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients","volume":"37","author":"Jahn","year":"2023","journal-title":"Leukemia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1182\/bloodadvances.2023010179","article-title":"Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: A global phase 3 randomized study","volume":"7","author":"Fenaux","year":"2023","journal-title":"Blood Adv."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood.2024025409","article-title":"Genetic risk classification for adults with AML receiving less-intensive therapies: The 2024 ELN recommendations","volume":"144","author":"DiNardo","year":"2024","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1002\/ajh.27070","article-title":"Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants","volume":"98","author":"Bataller","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1038\/s41375-018-0257-z","article-title":"Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care","volume":"32","author":"Dolnik","year":"2018","journal-title":"Leukemia"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-22-1183","article-title":"Outcomes in Patients with Poor-risk Cytogenetics with or Without TP53 Mutations Treated with Venetoclax and Azacitidine","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/ajh.27138","article-title":"Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients","volume":"99","author":"Gangat","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1111\/bjh.19292","article-title":"Novel stratification for newly diagnosed acute myeloid leukaemia treated with venetoclax-based therapy in the real world: Hokkaido Leukemia Net Study","volume":"204","author":"Miyashita","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1182\/blood.2024026925","article-title":"Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML","volume":"144","author":"Lachowiez","year":"2024","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2025-453","article-title":"Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: A multinational retrospective cohort study (abs 618A)","volume":"146","author":"Lachowiez","year":"2025","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1158\/2643-3230.BCD-25-0174","article-title":"A FABulous Couple: Adding PHENotype to GENotype Improves HMA\/VEN Response Prediction in AML","volume":"6","author":"Renders","year":"2025","journal-title":"Blood Cancer Discov."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3324\/haematol.2018.214882","article-title":"Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia","volume":"105","author":"Leppa","year":"2020","journal-title":"Haematologica"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/2159-8290.CD-22-0939","article-title":"Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine\/Venetoclax","volume":"13","author":"Waclawiczek","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1158\/2643-3230.BCD-24-0256","article-title":"Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study","volume":"6","author":"Lachowiez","year":"2025","journal-title":"Blood Cancer Discov."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4804","DOI":"10.1021\/bi200499m","article-title":"A tale of two subunits: How the neomorphic R132H IDH1 mutation enhances production of alphaHG","volume":"50","author":"Pietrak","year":"2011","journal-title":"Biochemistry"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate","volume":"17","author":"Ward","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","article-title":"Recurring mutations found by sequencing an acute myeloid leukemia genome","volume":"361","author":"Mardis","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1309\/AJCPD7NR2RMNQDVF","article-title":"Acute myeloid leukemia with IDH1 or IDH2 mutation: Frequency and clinicopathologic features","volume":"135","author":"Patel","year":"2011","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.cell.2012.06.023","article-title":"The origin and evolution of mutations in acute myeloid leukemia","volume":"150","author":"Welch","year":"2012","journal-title":"Cell"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1182\/bloodadvances.2020001503","article-title":"Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML","volume":"4","author":"Choe","year":"2020","journal-title":"Blood Adv."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1200\/JCO.2010.28.2285","article-title":"Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: A study by the Acute Leukemia French Association group","volume":"28","author":"Boissel","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1200\/JCO.2010.28.3762","article-title":"IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication","volume":"28","author":"Paschka","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41408-021-00497-1","article-title":"Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm","volume":"11","author":"Issa","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1158\/1078-0432.CCR-18-3749","article-title":"FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation","volume":"25","author":"Norsworthy","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_42","unstructured":"European Medicines Agency (2025, December 12). Medicines-Tibsovo. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tibsovo#authorisation-details."},{"key":"ref_43","unstructured":"(2025, December 12). CDA-AMC: Reimbursement Review: Rapid Provisional Funding Algorithm. Available online: https:\/\/www.cda-amc.ca\/sites\/default\/files\/DRR\/2025\/PH0082_Final_Report.pdf."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1001\/jamaoncol.2017.4695","article-title":"Differentiation Syndrome Associated with Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1\/2 Study","volume":"4","author":"Fathi","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1158\/1078-0432.CCR-20-0834","article-title":"Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis","volume":"26","author":"Norsworthy","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1182\/blood.2024024008","article-title":"How I treat acute myeloid leukemia with differentiation therapy","volume":"145","author":"Issa","year":"2025","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1182\/blood.2019004583","article-title":"Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?","volume":"136","author":"Kramer","year":"2020","journal-title":"Blood"},{"key":"ref_49","first-page":"2469","article-title":"Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens","volume":"109","author":"Baden","year":"2024","journal-title":"Haematologica"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","article-title":"Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/01.HS9.0000843412.59637.1b","article-title":"NPM1 mutated AML: Impact of Co-Mutational Patterns\u2014Results of The European Harmony Alliance (S130)","volume":"6","author":"Benner","year":"2022","journal-title":"HemaSphere"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/blood.2023021579","article-title":"Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy","volume":"143","author":"Othman","year":"2024","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/cas.14274","article-title":"FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development","volume":"111","author":"Kiyoi","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41586-024-08137-x","article-title":"RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax","volume":"636","author":"Sango","year":"2024","journal-title":"Nature"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic Classification and Prognosis in Acute Myeloid Leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_56","first-page":"S148","article-title":"Development and Independent Validation of Unsupervised Genomic Classification of Patients with Acute Myeloid Leukemia Using Hierarchical Dirichlet Mixture Models. A Harmony Alliance Study. (S148)","volume":"9","author":"Turki","year":"2025","journal-title":"Hemasphere"},{"key":"ref_57","first-page":"S126","article-title":"Chromatin Accessibility Profiling Reveals Epigenetic Heterogeneity in Acute Myeloid Leukemia (S126)","volume":"8","author":"Ochi","year":"2024","journal-title":"HemaSphere"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2025-6","article-title":"Results from PARADIGM\u2014A phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia","volume":"146","author":"Fathi","year":"2025","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e495","DOI":"10.1016\/S2352-3026(23)00089-3","article-title":"Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): A randomised, open-label, multicentre, phase 3 trial","volume":"10","author":"Dohner","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1182\/blood.2024024310","article-title":"Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML","volume":"144","author":"Othman","year":"2024","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1158\/2159-8290.CD-22-0366","article-title":"Mutant NPM1 Directly Regulates Oncogenic Transcription in Acute Myeloid Leukemia","volume":"13","author":"Uckelmann","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1158\/2159-8290.CD-22-0424","article-title":"Mutant NPM1 Hijacks Transcriptional Hubs to Maintain Pathogenic Gene Programs in Acute Myeloid Leukemia","volume":"13","author":"Wang","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1182\/blood.2025028357","article-title":"Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: The AUGMENT-101 study","volume":"146","author":"Arellano","year":"2025","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1200\/JCO-25-01694","article-title":"Ziftomenib in Relapsed or Refractory NPM1-Mutated AML","volume":"43","author":"Wang","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13045-025-01718-x","article-title":"Menin inhibitors from monotherapies to combination therapies: Clinical trial updates from 2024 ASH annual meeting","volume":"18","author":"Cao","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e71205","DOI":"10.1002\/cam4.71205","article-title":"Prevalence of Fms-Like Tyrosine Kinase 3 (FLT3) Mutations in Patients with Acute Myeloid Leukaemia: A Systematic Literature Review and Meta-Analysis","volume":"14","author":"Lewis","year":"2025","journal-title":"Cancer Med."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Kennedy, V.E., and Smith, C.C. (2020). FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.612880"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1007\/s11864-022-00991-z","article-title":"How Genetics Can Drive Initial Therapy Choices for Older Patients with Acute Myeloid Leukemia","volume":"23","author":"Moore","year":"2022","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1158\/1078-0432.CCR-21-3405","article-title":"Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naive Acute Myeloid Leukemia","volume":"28","author":"Konopleva","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1200\/JCO.23.01911","article-title":"Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML","volume":"42","author":"Short","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1182\/blood-2025-654","article-title":"Venetoclax and azacitidine with gilteritinib in patients with newly diagnosed FLT3mut+ Acute Myeloid Leukemia ineligible for intensive induction chemotherapy: Interim results from the phase 1\/2 VICEROY study","volume":"146","author":"Altman","year":"2025","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"6027","DOI":"10.1182\/blood-2024-199701","article-title":"A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A Myelomatch Treatment Trial: ECOG-ACRIN MM20A-EA02","volume":"144","author":"Altman","year":"2024","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"5345","DOI":"10.1182\/bloodadvances.2022007223","article-title":"Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications","volume":"6","author":"Weber","year":"2022","journal-title":"Blood Adv."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_77","first-page":"683.e1","article-title":"Clinical Outcomes and Treatment Patterns in Adults with FLT3-ITD(mut+) Acute Myeloid Leukemia Undergoing Allogeneic Hemopoietic Cell Transplantation in the United States and Canada","volume":"30","author":"Pandya","year":"2024","journal-title":"Transpl. Cell Ther."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia with Genomic Evidence of Residual Disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/jamaoncol.2024.0985","article-title":"Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia","volume":"10","author":"Dillon","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia with FLT3-Internal Tandem Duplication Mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e600","DOI":"10.1016\/S2352-3026(23)00117-5","article-title":"Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: Long-term follow-up of an open-label, multicentre, randomised, phase 3 trial","volume":"10","author":"Xuan","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_83","first-page":"2024","article-title":"Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial","volume":"110","author":"Schlenk","year":"2025","journal-title":"Haematologica"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.23.02474","article-title":"Gilteritinib as Post-Transplant Maintenance for AML with Internal Tandem Duplication Mutation of FLT3","volume":"42","author":"Levis","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission","volume":"383","author":"Wei","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/leu.2016.263","article-title":"The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: An analysis of 3307 cases","volume":"31","author":"Stengel","year":"2017","journal-title":"Leukemia"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1182\/blood.2022018236","article-title":"TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype","volume":"141","author":"Hiwase","year":"2023","journal-title":"Blood"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41408-024-01186-5","article-title":"What have we learned about TP53-mutated acute myeloid leukemia?","volume":"14","author":"Shahzad","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1080\/10428194.2024.2344057","article-title":"Evaluating targeted therapies in older patients with TP53-mutated AML","volume":"65","author":"Sabile","year":"2024","journal-title":"Leuk. Lymphoma"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s12185-016-1942-1","article-title":"TP53 mutations in older adults with acute myeloid leukemia","volume":"103","author":"Yanada","year":"2016","journal-title":"Int. J. Hematol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13045-023-01417-5","article-title":"Treatment outcomes for newly diagnosed, treatment-naive TP53-mutated acute myeloid leukemia: A systematic review and meta-analysis","volume":"16","author":"Daver","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"5540","DOI":"10.1182\/bloodadvances.2023010312","article-title":"Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDS","volume":"7","author":"Stengel","year":"2023","journal-title":"Blood Adv."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","article-title":"Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes","volume":"26","author":"Bernard","year":"2020","journal-title":"Nat. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13045-023-01480-y","article-title":"Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia","volume":"16","author":"Bahaj","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood.2024024245","article-title":"TP53-mutated acute myeloid leukemia: How can we improve outcomes?","volume":"145","author":"Sallman","year":"2025","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1182\/bloodadvances.2023010417","article-title":"Utility or futility? A contemporary approach to allogeneic hematopoietic cell transplantation for TP53-mutated MDS\/AML","volume":"8","author":"Nawas","year":"2024","journal-title":"Blood Adv."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41375-023-01847-7","article-title":"Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)","volume":"37","author":"Badar","year":"2023","journal-title":"Leukemia"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1182\/blood-2018-02-832360","article-title":"Prognostic factors influencing survival after allogeneic transplantation for AML\/MDS patients with TP53 mutations","volume":"131","author":"Ciurea","year":"2018","journal-title":"Blood"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1182\/bloodadvances.2021004319","article-title":"The Simplified Comorbidity Index: A new tool for prediction of nonrelapse mortality in allo-HCT","volume":"6","author":"Shouval","year":"2022","journal-title":"Blood Adv."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/bjh.19055","article-title":"The Simplified Comorbidity Index predicts non-relapse mortality in reduced-intensity conditioning allogeneic haematopoietic cell transplantation","volume":"203","author":"Elias","year":"2023","journal-title":"Br. J. Haematol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/7\/431\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T04:27:58Z","timestamp":1784608078000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/7\/431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,18]]},"references-count":101,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["curroncol33070431"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33070431","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,18]]}}}